Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
We evaluated the ability of the commercial Sentosa SQ Hepatitis C Virus Genotyping Assay to identify the HCV genotype subtype in patients from The Gambia. Subtype was determined from the Sentosa-generated NS5B sequences using 3 bioanalytical methods: the Sentosa SQ HCV Genotyping Assay bioanalytical tool, Geno2pheno, and the National Reference Center in-house method. The Sentosa assay result agreed with the reference method in only 2 of 13 cases. This study highlights the difficulty of correctly identifying HCV subtypes in a region of Africa with a high diversity of HCV genotype 1 and 2 subtypes that may be resistant to antivirals.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/infdis/jiaf378 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
RE: Prophylactic antiviral therapy and all-cause mortality in cancer patients with hepatitis B e antigen-negative chronic hepatitis B virus infection receiving immunosuppressive therapy.
J Natl Cancer Inst
September 2025
Department of Gastroenterology and Hepatology, Sincan Training and Research Hospital, Ankara, Turkey.
Navigating Hepatitis C care: Knowledge gaps and access barriers among young women who inject drugs in rural Appalachia.
PLoS One
September 2025
Wake Forest University School of Medicine, Department of Implementation Science, Winston-Salem, North Carolina, United States of America.
Background: Hepatitis C virus (HCV) and injection drug use among young women are dramatically rising in the rural United States. From 2004 to 2017, heroin use among non-pregnant women increased 22.4% biennially, mirroring increases in HCV cases, especially among younger populations.
View Article and Find Full Text PDFBayesian estimation of HIV acquisition dates for prevention trials.
mBio
September 2025
Fred Hutchinson Cancer Center, Vaccine and Infectious Disease Division, Seattle, Washington, USA.
Accurate timing estimates of when participants acquire HIV in HIV prevention trials are necessary for determining antibody levels at acquisition. The Antibody-Mediated Prevention (AMP) Studies showed that a passively administered broadly neutralizing antibody can prevent the acquisition of HIV from a neutralization-sensitive virus. We developed a pipeline for estimating the date of detectable HIV acquisition (DDA) in AMP Study participants using diagnostic and viral sequence data.
View Article and Find Full Text PDFClinical Impact of Continuation Versus Cessation of Antiviral Therapy in Chronic Hepatitis B: A Modelling Study With Implications for Hepatitis B Cure.
J Viral Hepat
October 2025
Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
Discontinuing antivirals in chronic hepatitis B virus (HBV) 'e' antigen negative infection can enhance HBV surface antigen (HBsAg) loss but risks complications. We modelled the clinical impact of discontinuing antivirals in chronic HBV. We developed a Markov state model with Monte Carlo simulation of chronic HBV to compare continuation of antiviral therapy with 3 strategies of cessation and reinitiation for: (1) virologic relapse, (2) clinical relapse, or (3) hepatitis flare.
View Article and Find Full Text PDFHepatitis B Virus in Jordan: Prevalence, Incidence and Clearance From Cross-Sectional and Cohort Studies.
J Viral Hepat
October 2025
Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.
Hepatitis B virus (HBV) infection is a global health challenge, with the World Health Organization (WHO) targeting its elimination by 2030. Jordan lacks sufficient data on HBV epidemiology, including prevalence, incidence and clearance. This study addresses these gaps through a retrospective analysis of HBV testing data from 40,268 individuals collected at Biolab Diagnostic Laboratories (2010-2024).
View Article and Find Full Text PDF